^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NEK11 (NIMA Related Kinase 11)

    i
    Other names: NEK11, NIMA Related Kinase 11, NIMA (Never In Mitosis Gene A)- Related Kinase 11, Serine/Threonine-Protein Kinase Nek11, Never In Mitosis A-Related Kinase 11, NimA-Related Protein Kinase 11, FLJ23495
    4d
    Mutational insights and in silico characterization of NEK family kinases in OSCC patients from the Pakistani population. (PubMed, Front Bioinform)
    Mutations including NEK11p.E347V (31/31), NEK9p.R429H (23/31), NEK10p.L513S (15/31), NEK4p.P136A (7/31), NEK5p.K255Q (6/31) and NEK1 p.E650G (5/31) were found to be recurring mutations and can be validated further in large-scale studies for biomarker applicability. Collectively, these findings suggest NEK mutations as candidate drivers of OSCC pathogenesis, underscoring their potential as prognostic biomarkers and therapeutic targets, particularly in tobacco-associated disease.
    Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    5ms
    N6-Methyladenosine-Modified circNEK11 Promotes Hepatocellular Carcinoma Progression via the miR-1236-3p/GPX2 Axis. (PubMed, Cancer Sci)
    Mechanistically, circNEK11 directly binds to miR-1236-3p to regulate GPX2 expression, thus promoting HCC progression and recurrence. Collectively, our findings suggest that circNEK11 is a potential biomarker and target for HCC diagnosis and treatment.
    Journal
    |
    GPX2 (Glutathione peroxidase 2 (gastrointestinal)) • NEK11 (NIMA Related Kinase 11) • YTHDC1 (YTH Domain Containing 1)
    11ms
    Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases. (PubMed, Cancer Biomark)
    However, further efforts are necessary to validate their clinical value for diagnosis and prognosis and to develop practical applications in clinical settings. Nevertheless, these pan-cancer profiles offer a better overall understanding as well as useful information for future reference regarding mitotic DNA integrity checkpoint signaling in cancer.
    Journal • BRCA Biomarker • Pan tumor
    |
    BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • NEK11 (NIMA Related Kinase 11) • PLK2 (Polo Like Kinase 2) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    12ms
    Targeting NEK Kinases in Gastrointestinal Cancers: Insights into Gene Expression, Function, and Inhibitors. (PubMed, Int J Mol Sci)
    Specifically, an NEK2 inhibitor, T-1101 tosylate, is currently undergoing clinical trials. This review will focus on the gene expression and functional roles of NEKs in GI cancers, as well as the progress in developing NEK inhibitors.
    Review • Journal • IO biomarker
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    over1year
    Prognostic value and immune infiltration of the NEK family in clear cell renal cell carcinoma. (PubMed, Medicine (Baltimore))
    These results indicate that NEK family members are significantly differentially expressed in ccRCC, and a significant correlation exists between the NEK family and prognosis and immune infiltration. NEK family members may act as therapeutic targets and prognostic indicators in ccRCC.
    Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    almost2years
    Prognostic value and therapeutic potential of NEK family in stomach adenocarcinoma. (PubMed, J Cancer)
    Our results suggest that NEK9 in particular has the potential to be used as a diagnostic and prognostic biomarker of STAD development and progression and an immune target for treatment of the disease. These findings expand our understanding of the biological functions of the NEK family members in STAD.
    Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    2years
    Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers (YIR 2024)
    Taken together, these results demonstrate that fusion RNAs in MBC—some recurrent, many highly expressed and unique to individual tumors—are common. We create the most comprehensive catalog of ESR1 fusions in MBC, better define their frequency, discover their enrichment in LumB-like tumors, and will discuss clinicopathologic and transcriptomic features associated with ESR1 fusion positive disease. We identify druggable fusions that would likely be missed by current testing standards, find recurrent loss-of-function fusion RNAs, and show that over one-third of metastatic cases harbor at least one outlier expressed fusion—many of which involve BrCarelated genes.
    BRCA Biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • NF1 (Neurofibromin 1) • CDH1 (Cadherin 1) • CREBBP (CREB binding protein) • ARID1B (AT-Rich Interaction Domain 1B) • FOXP1 (Forkhead Box P1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • TGFB1 (Transforming Growth Factor Beta 1) • AXIN1 (Axin 1) • MSI2 (Musashi RNA Binding Protein 2) • NEK11 (NIMA Related Kinase 11) • PRKCA (Protein Kinase C Alpha) • PIK3R3 (Phosphoinositide-3-Kinase Regulatory Subunit 3) • USP32 (Ubiquitin Specific Peptidase 32)
    |
    FGFR2 fusion • BRCA mutation • CDH1 expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    over2years
    Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM) (ASH 2023)
    We showed superior prognostic value of CTC and MRD kinetics over single assessments. Tumor dissemination seems to be driven by transcriptional priming rather than acquired secondary genetic events, while on-treatment resistance is linked to genomic and transcriptional evolution, without recurrent genetic alterations and with common molecular signatures of resistance.
    Circulating tumor cells • Tumor cell
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NEK11 (NIMA Related Kinase 11) • DIS3 (DIS3 Homolog, Exosome Endoribonuclease And 3'-5' Exoribonuclease)
    |
    BRAF mutation
    almost4years
    Integrative Analysis of the Expression Levels and Prognostic Values for NEK Family Members in Breast Cancer. (PubMed, Front Genet)
    Our studies show the prognosis values of the NEKs in BC. Thus, we suggest that NEKs may be regarded as novel biomarkers for predicting potential prognosis values and potential therapeutic targets of BC patients.
    Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    4years
    The NEK family of serine/threonine kinases as a biomarker for cancer. (PubMed, Clin Exp Med)
    Furthermore, we have comprehensively reviewed the NEK kinases in terms of their expression and regulation in different cancers. Lastly, we have emphasized on some of the potential NEK inhibitors reported so far.
    Review • Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    4years
    Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer. (PubMed, J Pers Med)
    Moreover, Tumor Immune Estimation Resource (TIMER) results showed that the transcriptional levels of NEK2 were positively correlated with immune infiltration of B cells and CD4 T Cell. Collectively, the current study indicated that NEK family genes, especially NEK2 which is involved in immune infiltration, and may serve as prognosis biomarkers for breast cancer progression.
    Journal
    |
    CD4 (CD4 Molecule) • NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)
    over4years
    NEK7 promotes gastric cancer progression as a cell proliferation regulator. (PubMed, Cancer Cell Int)
    NEK7 exerts a regulatory effect on cell proliferation and is closely related to tumor immune infiltration.
    Journal
    |
    NEK11 (NIMA Related Kinase 11) • NEK1 (NIMA Related Kinase 1)